We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Tuesday, H.C. Wainwright adjusted its price target for Tourmaline Bio (NASDAQ:TRML), increasing it to $49.00 from the previous $48.00, while reaffirming a Buy rating on the ...

Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its investors. Tourmaline Bio, Inc. is a clinical-stage ...

On Friday, Guggenheim reaffirmed its Buy rating on shares of Tourmaline Bio (NASDAQ:TRML), maintaining its current price target. The update followed a meeting with ...